Vulvodynia Treatment Market: Global Industry Analysis and Forecast (2022-2029)

Vulvodynia Treatment Market size was valued at US$ 3.37 Bn. in 2021 and the total revenue is expected to grow at 4.3% through 2021 to 2029, reaching nearly US$ 4.73 Bn.

Vulvodynia Treatment Market Overview:

Vulvodynia is a painful condition that affects the vulva (outer female genitals). It frequently lasts for more than three months, and the cause is unknown. Even though vulvodynia is the most common cause of painful sex in women who haven't reached menopause, it's difficult to say how widespread it is. Many women find it difficult to bring up the issue with their doctor. Once they do, clinicians can easily misdiagnose vulvodynia as something different. Researchers are working hard to figure out what's causing it and how to cure it better.Vulvodynia Treatment MarketTo know about the Research Methodology :- Request Free Sample Report

Vulvodynia Treatment Market Dynamics:

The expanding concerns and awareness campaigns linked to women's healthcare, developments in healthcare facilities and diagnostic services, and the availability of a large number of generic products are the key driving drivers. The market is likely to be driven by an increase in the number of research and development activities. SLU scientists, for example, examined the potential biomarkers for pain linked to debilitating health conditions like chemotherapy-induced peripheral neuropathy (CIPN), endometriosis, interstitial cystitis, and vulvodynia in an article published on February 16, 2021, with $363,000 in new funding from the Mayday Fund. Over the forecast period, the increased incidence of vulvodynia is expected to boost market expansion. According to a University of Michigan research, one out of every four women would have vulvar pain at some point in their lives. Vulvar pain, like all other medical issues, produces both physical and mental stress. Over the forecast period, the presence of a strong product pipeline is expected to boost market expansion. As an example, Low awareness, the emergence of side effects from treatment drugs, and the absence of a medical diagnosis are all predicted to limit market expansion. Hives, difficulty breathing, swelling of the face, lips, tongue, or throat, blurred vision, and other treatment-related side effects are likely to stymie market expansion.

Vulvodynia Treatment Market Segment Analysis:

The anti-convulsant segment is dominating the Drug Type segment of the Vulvodynia Treatment Market: Over the projected period, the anti-convulsant segment is expected to increase at a rapid pace. Anticonvulsants are the most commonly given medication for vulvodynia treatment. Gabapentin is the most effective anticonvulsant medicine for the treatment of vulvodynia. Gabapentin is a medicine that has been proven to be beneficial in the treatment of chronic pain. Another anticonvulsant is pregabalin. Gabapentin is a drug that is comparable to this. However, it has been shown to have fewer negative effects and may be more effective. The existence of a growing number of research and development activities is projected to help the market grow. According to an article published in the American Journal of Obstetrics and Gynecology in 2021, oral nerve pain drug Gabapentin increased sexual function in women with vulva pain. The Hospital segment is considered to supplement the growth of the Vulvodynia Treatment Market. The hospital Segment is dominating the growth of the vulvodynia Treatment market with a market share of 64.6% in 2021. There are two type of vulvodynia such as generalizes vulvodynia and localized vulvodynia. Growing healthcare system and infrastructure, adoption of higher medical facilities in treatment by the hospital authorities are likely to boost the growth of the market in the forecast period. further, the rising prevalence of vulvodynia is anticipated to lift the growth of the hospital segment in the forecast period. Also, increasing awareness regarding the treatment and huge investment by the government agencies in the market is further estimated to drive the growth of the market.

Vulvodynia Treatment Market Regional Insights:

North America is estimated to dominate the growth of the Vulvodynia Treatment Market. Over the forecast period, the increased prevalence of vulvodynia is expected to boost market growth. According to a Harvard study financed by the National Institutes of Health, an estimated 6 million women in the United States will suffer from Vulvodynia. Despite the large number of people who are affected, the pain is frequently misdiagnosed or ignored. Further, due to the increased prevalence of vulvodynia and the presence of continuous research and development efforts in the region, North America dominated the worldwide vulvodynia treatment market in 2021 and is expected to continue to do so over the forecast period. According to the University of Michigan, 25 % of the 2,269 women in the metro-Detroit area had experienced vulvar pain. Only 2% of those in the 25 % reported seeking medical help for their pain. Although it is upsetting to learn that few women speak up about their pain, it is even more alarming to learn that those who did talk to their doctor about their discomfort were misdiagnosed. According to the National Vulvodynia Association in the United States, up to 16% of women encounter the illness at some point throughout their lives. Over the forecast period, the presence of continuous research and development activities on vulvodynia treatment is expected to boost market expansion. As an example, The objective of the report is to present a comprehensive analysis of the Vulvodynia Treatment Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Vulvodynia Treatment Market dynamics, structure by analyzing the market segments and project the Vulvodynia Treatment Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Vulvodynia Treatment Market make the report investor’s guide.

Vulvodynia Treatment Market Scope: Inquire before buying

Vulvodynia Treatment Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: US $ 3.37 Bn.
Forecast Period 2022 to 2029 CAGR: 4.3% Market Size in 2029: US $ 4.73 Bn.
Segments Covered: by Drug Type • Anticonvulsants • Tricyclic antidepressants • Local anesthetics • Antimicrobials • Hormone creams • Nerve blocks • others
by End-User • Hospital Pharmacies • Retail pharmacies • Online pharmacies

Vulvodynia Treatment Market, by Region

North America (United States, Canada and Mexico) • Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) • Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) • Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) • South America (Brazil, Argentina Rest of South America)

Vulvodynia Treatment Market Key Player

Teva Pharmaceutical Industries Ltd • Cipla Inc • Amneal Pharmaceuticals Inc • Glenmark Pharmaceuticals Inc • Alkem Labs • Taro Pharmaceutical Industries Ltd • Mylan N.V. • Eli Lilly and Company • Allergan • Zydus Cadila • Hikma Pharmaceuticals PLC • Allergan • Janssen Pharmaceuticals (Johnson and Johnson) • GTO Pharmaceutical, LLC • Ipsen Pharma

FAQs:

1. What is the Vulvodynia Treatment market value in 2021? Ans: Vulvodynia Treatment market value in 2021 was estimated as 3.37 Billion USD. 2. What is the Vulvodynia Treatment market growth? Ans: The Vulvodynia Treatment market is anticipated to grow with a CAGR of 4.3% in the forecast period and is likely to reach USD 4.73 Billion by the end of 2029. 3. Which End-User segment is expected to dominate the Vulvodynia Treatment market during the forecast period? Ans: The Hospital segment is projected to lead the market growth and held the largest market share of 4.3% in 2021. 4. Who are the key players in the Vulvodynia Treatment market? Ans: Some key players operating in the Vulvodynia Treatment market include Teva Pharmaceutical Industries Ltd, Cipla Inc, Amneal Pharmaceuticals Inc, Glenmark Pharmaceuticals Inc, Alkem Labs, Taro Pharmaceutical Industries Ltd, Mylan N.V., Eli Lilly and Company, Allergan, Zydus Cadila, and Hikma Pharmaceuticals PLC among others. 5. What is the key driving factor for the growth of the Vulvodynia Treatment market? Ans: The factors that propelled the growth of the vulvodynia treatment market are the rise in vulvodynia patients as well as the availability of various therapeutic agents and vulnerable women population would influence the demand for a novel treatment for vulvodynia.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Vulvodynia Treatment Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2021 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Vulvodynia Treatment Market 3.4. Geographical Snapshot of the Vulvodynia Treatment Market, By Manufacturer share 4. Vulvodynia Treatment Market Overview, 2021-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porter Five Forces Analysis 4.1.6.1. The threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. The threat of Substitute Grades 4.1.6.5. The intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Vulvodynia Treatment Market 5. Supply Side and Demand Side Indicators 6. Vulvodynia Treatment Market Analysis and Forecast, 2021-2029 6.1. Vulvodynia Treatment Market Size & Y-o-Y Growth Analysis. 7. Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 7.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 7.1.1. Anticonvulsants 7.1.2. Tricyclic antidepressants 7.1.3. Local anesthetics 7.1.4. Antimicrobials 7.1.5. Hormone creams 7.1.6. Nerve blocks 7.1.7. others 7.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 7.2.1. Hospital Pharmacies 7.2.2. Retail pharmacies 7.2.3. Online pharmacies 8. Vulvodynia Treatment Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2021-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 9.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 9.1.1. Anticonvulsants 9.1.2. Tricyclic antidepressants 9.1.3. Local anesthetics 9.1.4. Antimicrobials 9.1.5. Hormone creams 9.1.6. Nerve blocks 9.1.7. others 9.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 9.2.1. Hospital Pharmacies 9.2.2. Retail pharmacies 9.2.3. Online pharmacies 10. North America Vulvodynia Treatment Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 11.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 11.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 12. Canada Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 12.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 12.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 13. Mexico Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 13.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 13.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 14. Europe Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 14.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 14.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 15. Europe Vulvodynia Treatment Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 16.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 16.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 17. France Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 17.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 17.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 18. Germany Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 18.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 18.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 19. Italy Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 19.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 19.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 20. Spain Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 20.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 20.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 21. Sweden Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 21.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 21.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 22. CIS Countries Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 22.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 22.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 23. Rest of Europe Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 23.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 23.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 24. Asia Pacific Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 24.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 24.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 25. Asia Pacific Vulvodynia Treatment Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 26.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 26.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 27. India Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 27.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 27.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 28. Japan Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 28.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 28.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 29. South Korea Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 29.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 29.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 30. Australia Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 30.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 30.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 31. ASEAN Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 31.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 31.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 32. Rest of Asia Pacific Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 32.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 32.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 33. Middle East Africa Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 33.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 33.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 34. Middle East Africa Vulvodynia Treatment Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 35.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 35.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 36. GCC Countries Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 36.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 36.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 37. Egypt Textile Reinforced Concrete e-Market Analysis and Forecasts, 2021-2029 37.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 37.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 38. Nigeria Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 38.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 38.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 39. Rest of ME&A Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 39.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 39.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 40. South America Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 40.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 40.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 41. South America Vulvodynia Treatment Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 42.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 42.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 43. Argentina Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 43.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 43.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 44. Rest of South America Vulvodynia Treatment Market Analysis and Forecasts, 2021-2029 44.1. Market Size (Value) Estimates & Forecast By Drug Type, 2021-2029 44.2. Market Size (Value) Estimates & Forecast By End-User, 2021-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Vulvodynia Treatment Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment 45.2.2. New Grade Launches and Grade Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. Novartis AG 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Grade Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Development 45.3.2. Teva Pharmaceutical Industries Ltd 45.3.3. Cipla Inc 45.3.4. Amneal Pharmaceuticals Inc 45.3.5. Glenmark Pharmaceuticals Inc 45.3.6. Alkem Labs 45.3.7. Taro Pharmaceutical Industries Ltd 45.3.8. Mylan N.V. 45.3.9. Eli Lilly and Company 45.3.10. Allergan 45.3.11. Zydus Cadila 45.3.12. Hikma Pharmaceuticals PLC 46. Primary Key Insights
  • INQUIRE BEFORE BUYING